4D Molecular Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

Rhea-AI Summary

4D Molecular Therapeutics (Nasdaq: FDMT) has announced participation in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 2:30 p.m. PT. This event will feature a fireside chat available via a live audio webcast on the company's website, with a replay accessible for two weeks after the event. 4DMT focuses on advancing gene therapy through its Therapeutic Vector Evolution platform, targeting areas like ophthalmology and cardiology, with ongoing clinical trials for multiple diseases including XLRP, choroideremia, and Fabry disease.

EMERYVILLE, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8 at 2:30 p.m. PT.

A live audio webcast of the fireside chat will be available by visiting the “Investors & Media” section of the 4DMT website at www.4dmoleculartherapeutics.com. A replay of the webcast will be available for at least two weeks following the live event.

About 4DMT

4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP patients, 4D-110 is in a Phase 1 clinical trial for choroideremia patients and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease patients.

4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

Contacts:

Media:

Theresa Janke
tjanke@4dmt.com

Investors:

Mike Zanoni
Endurance Advisors
mzanoni@4dmt.com

FAQ

When is the Goldman Sachs 42nd Annual Global Healthcare Conference for FDMT?

The conference will take place on June 8, 2021, at 2:30 p.m. PT.

How can I listen to the FDMT presentation at the conference?

You can access the live audio webcast through the 'Investors & Media' section of the 4D Molecular Therapeutics website.

What are the main focus areas of 4D Molecular Therapeutics?

4D Molecular Therapeutics focuses on gene therapy in ophthalmology, cardiology, and pulmonology.

What trials is FDMT currently conducting?

FDMT is conducting three clinical trials: 4D-125 for XLRP, 4D-110 for choroideremia, and 4D-310 for Fabry disease.

What is Therapeutic Vector Evolution?

Therapeutic Vector Evolution is 4DMT's platform for developing targeted gene therapies by combining directed evolution with synthetic capsid sequences.